Your AI-Trained Oncology Knowledge Connection!
WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.
WASHINGTON--President Clinton has appointed Dr. Jeffrey P. Koplan, an epidemiologist, as director of the Centers for Disease Control and Prevention, replacing Dr. David Satcher, who left last February to become Surgeon General. Dr. Koplan was with the CDC for most of his career, starting in 1972, until leaving 4 years ago to join Prudential Healthcare as president of its Center for Health Care Research.
TORONTO--Intensive chemotherapy can cure patients with high-grade non-Hodgkin’s lymphoma (NHL), but many patients fail to enter complete remission or relapse after a complete response.
CHAPEL HILL, NC--Although the health care professional is often to blame when cancer pain management is inadequate, barriers to pain control can also stem from patients’ forgetfulness, stoicism, and fatalism. "A cancer pain management plan cannot be effective if patients fail to report pain and adhere to treatment recommendations," said
Roger Byhardt, MD, professor of radiation oncology and member of the Cancer Center of the Medical College of Wisconsin, has been named principal investigator of a $355,700 grant to help improve the access of veterans and other military personnel
NIAGARA-ON-THE-LAKE, Ontario, Canada--While the collection of sperm from adult males prior to cancer treatment is a routine matter, the same issue has not yet been regularly introduced into adolescent clinics.
Researchers at the University of Texas (UT) Southwestern Medical Center in Dallas are offering the first plausible, molecular explanation of the behavior of the human immunodeficiency virus (HIV) in people with syphilis. The virus is transmitted more
WASHINGTON--Although the role of erythropoietin, or epoetin (Epogen, Procrit), in the treatment of chemotherapy-induced anemia is generally well known and accepted, its potential for prophylactic use to prevent the development of anemia in cancer patients remains at issue.
Athough managed care represents a major change from the way many cancer centers have traditionallydone business, it is
WASHINGTON--Following the demise of the McCain comprehensive tobacco bill in the US Senate, House Republicans offered an outline of new, less extensive antitobacco legislation they plan to draft.
NEW YORK--Using x-ray crystallography, researchers have managed to catch an HIV surface glycoprotein (gp120) in the act of binding to a CD 4T-cell receptor (Figure 1). The images are a collaborative effort led by researchers from Columbia University College of Physicians & Surgeons and Dana-Farber Cancer Institute.
Use of hematopoietic colony-stimulating factors (CSFs) following induction and consolidation chemotherapy for elderly patients with acute myeloid leukemia (AML) is a controversial area. Studies have shown that CSFs can decrease the likelihood and/or shorten the duration of therapy-related neutropenic complications when given following induction chemotherapy.[1-7]
Current controversies in the treatment of stage I seminoma center on the relative roles of surveillance, adjuvant radiotherapy (RT), and adjuvant single-agent chemotherapy. Surveillance has been studied in over 800 patients,
Current controversies in the treatment of stage I seminoma center on the relative roles of surveillance, adjuvant radiotherapy (RT), and adjuvant single-agent chemotherapy. Surveillance has been studied in over 800 patients,
Nearly a decade ago, irinotecan (CPT-11 [Camptosar]) began clinical development in Japan. Early clinical trials in that country recognized its anti-tumor activity in a variety of advanced malignancies, including stomach, colon, cervical, and lung
Radiosurgery uses stereotactic targeting methods to precisely deliver highly focused, large doses of radiation to small intracranial tumors and arteriovenous malformations (AVMs). This article reviews the most common
Phase I trials of irinotecan (CPT-11 [Camptosar]), conducted at Johns Hopkins and the University of Texas, San Antonio, demonstrated some activity in patients with refractory advanced cancer. Three pivotal phase II studies of
Advanced gastric carcinoma remains an incurable disease with a median survival of 6 to 9 months, and available therapeutic approaches are predominantly palliative. In small controlled trials, systemic chemotherapy has
Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems
Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to
Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach
The objective response rate is the initial method to assess the activity of a novel anticancer agent. Response rates may not characterize a new agent’s clinical benefit, however, especially if moderate to severe toxicity may be
It has been hypothesized that intratumoral thymidylate synthase (TS) gene expression might be used to select therapy for patients with disseminated colorectal cancer. We recently
Based on high tumoricidal activity of the camptothecin analogs topotecan (Hycamtin), irinotecan (CPT-11[Camptosar]), and 9-aminocamptothecin (9-AC) in preclinical studies, clinical trials began testing these agents
Irinotecan (CPT-11 [Camptosar]) is an important new chemotherapeutic drug that demonstrates activity against a broad spectrum of malignancies, including carcinomas of the colon, stomach, and lung. Unfortunately, frequent and
The unique mechanism of action of irinotecan (CPT-11 [Camptosar]), topoisomerase I inhibition, together with the results of preclinical studies, suggest that the drug’s antitumor and toxicologic effects may be schedule-dependent.
Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed
LOS ANGELES--If the basic protocol for imparting bad news to cancer patients could be reduced to a T-shirt slogan, it would be, "Before you tell, ask," Robert Buckman, MD, PhD, said at an educational session on breaking bad news to cancer patients at the American Society of Clinical Oncology (ASCO) meeting. "Find out the patient’s expectations before you give information," he said.
WASHINGTON--Up to one-third of callers to the National Cancer Institute’s hot line for cancer information(1-800-4-CANCER) get a busy signal or hang up because of the long wait for someone to pick up, according to a report by the inspector general of the Department of Health and Human Services.
LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.
